Investigation into Alto Neuroscience, Inc. Securities Class Action

Strategic Insights -

The law firm Faruqi & Faruqi, LLP is investigating potential claims against Alto Neuroscience, Inc. regarding its initial public offering (IPO) conducted in February 2024 and subsequent stock performance. Investors who suffered losses of over $50,000 in Alto stock are encouraged to contact partner Josh Wilson directly to discuss their options. A federal securities class action has been filed against the company, with a September 19, 2025 deadline to seek the role of lead plaintiff.

Key Takeaways:

  • The complaint alleges that Alto and its executives made false and/or misleading statements and/or failed to disclose the effectiveness of ALTO-100 in treating major depressive disorder (MDD).
  • The company's clinical, regulatory, and commercial prospects for ALTO-100 were allegedly overstated, leading to an overstatement of the company's business and/or financial prospects.
  • The stock price of Alto fell significantly after the company announced topline results from the Phase 2b trial evaluating ALTO-100 on October 22, 2024.
  • Analysts, including Jeffries, reduced their price targets for Alto and questioned the company's overall biomarker approach to CNS disorders and psychiatry.
  • The court-appointed lead plaintiff directs and oversees the litigation on behalf of the putative class, but any member of the putative class may move the Court to serve as lead plaintiff or remain an absent class member.

Statistics:

  • Alto's stock price fell $10.17 per share, or 69.99%, to close at $4.36 per share on October 23, 2024, after the company announced its Phase 2b trial results.
  • The IPO was conducted on or about February 2, 2024.
  • The September 19, 2025 deadline is the last day for investors to seek the role of lead plaintiff in a federal securities class action filed against Alto.

Sources:

  • www.faruqilaw.com
  • Newsfile Corp. - August 19, 2025